IMUX - NASDAQ
Immunic, Inc.
$14.66
+2.3%Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
At a Glance
Live SnapshotImmunic, Inc. Management Team
Mr. Patrick Walsh
Chief Business Officer
Mr. Werner Gladdines
Chief Development Officer
Dr. Daniel Vitt Ph.D.
Chief Executive Officer & Director
Compensation
$777,749
Mr. Glenn Whaley CPA
Chief Financial Officer
Compensation
$534,000
Dr. Andreas Muehler M.D., Ph.D.
Chief Medical Officer
Compensation
$616,121
Mr. Jason Tardio M.B.A.
Chief Operating Officer & President
Compensation
$360,000
Dr. Hella Kohlhof
Chief Scientific Officer
Dr. Duane D. Nash J.D., M.B.A., M.D.
Executive Chairman
Compensation
$466,099
Mr. Inderpal Singh
General Counsel
Ms. Jessica Breu
Head of Investor Relations & Communications
Immunic, Inc. Insider Positioning
During the last 12 months, insiders have purchased $7.87M worth of IMUX shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
10.2M
7.87M
0
0.00
+7.9M
+$7.87M
Top Buyers
Vitt Daniel
Director, Officer: Ceo And Director
$3.06M
Muehler Andreas
Officer: Chief Medical Officer
$1.18M
Nash Duane
Director, Officer: Executive Chairman
$1.13M
Whaley Glenn
Officer: Chief Financial Officer
$994K
Tardio Jason
Officer: President And Coo
$727K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $7.87M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
IMUX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | May 29, 2026 | June 29, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 02, 2026 | April 14, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 22, 2025 | June 04, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 23, 2024 | June 11, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | February 05, 2024 | March 04, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 01, 2023 | June 28, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 15, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 27, 2021 | June 10, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | July 02, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | June 18, 2019 | July 16, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.